期刊文献+

垂体生长激素腺瘤经蝶入路手术预后因素分析 被引量:3

Analysis of factors influencing effect of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma
下载PDF
导出
摘要 目的评价垂体生长激素腺瘤经蝶手术的疗效和分析影响手术疗效的相关因素。方法回顾性分析106例资料完整经蝶手术治疗的垂体生长激素腺瘤病人的临床资料,根据肿瘤大小、术前生长激素水平、侵袭性等进行分类。随访术后激素水平、影像学检查评价手术疗效。结果垂体生长激素腺瘤患者进行经蝶手术后总缓解率为72.6%,Ⅰ级缓解率为84.2%,Ⅱ级为82.6%,Ⅲ级为64.7%,Ⅳ级为14.4%。Knosp 0、1、2、3、4级术后患者缓解率分别为89.7%、80.6%、66.7%、45.5%、0.0%。结论患者术前生长激素(growth hormone,GH)>30μg/L、肿瘤侵袭度>Ⅱ级是影响预后的危险因素;随肿瘤发展对患者颈内动脉包裹程度增加,术后缓解率显著下降。生长激素腺瘤患者缓解率和肿瘤大小、侵袭性、术前GH水平显著相关。 Objective To evaluate the therapeutic effect of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma(GHPA) and analyze the correlative factors influencing the effect. Methods The clinical data of 106 patients who underwent transsphenoidal microsurgery for GHPA were retrospectively analyzed.The tumors were classified according to tumor size,preoperative GH levels,and invasion etc.Based on the criterion of cure of acromegaly,postoperative hormone level and imaging examination were used to evaluate the post-operative outcomes. Results Total remission rate was 72.6%,and grades Ⅰ,Ⅱ,Ⅲ,and Ⅳ adenomas were 84.2%,82.6%,64.7%,and 14.4%,respectively.But according to Knosp grading,the remission rate of 0~4 grade were 89.7%,80.6%,66.7%,45.5% and 0.0%,respectively. Conclusion The prognoses were related to the size of the adenomas,the preoperative level of GH and invasiveness of GH-secreting adenomas.
出处 《首都医科大学学报》 CAS 北大核心 2011年第5期688-691,共4页 Journal of Capital Medical University
关键词 垂体腺瘤 肢端肥大症 经蝶手术 生长激素 pituitary adenomas acromegaly transsphenoidal surgery growth hormone
  • 相关文献

参考文献11

  • 1Orme S M,McNally R J,Cartwright R A.Morality and cancer incidence in acromegaly:a retrospective cohort study,United Kingdom Acromegaly Study Group[J].Clin Endocrinol Metab,1998,83(8):2730-2734.
  • 2Wilson C B.A decade of pituitary microsurgery:The herbert olivercrona lecture[J].J Neurosury,1984,61 (5):814-833.
  • 3Knosp E,Steiner E,Kitz K,et al.Pituitary adenomas with invasion of the cavernous sinus space:a magnetic resonance imaging classification compared with surgical findings[J].Neurosurgery,1993,33(4):610-617.
  • 4Swearingen B,Barker I I F,Katznelson L,et al.Longterm mortality after transsphenoidal surgery and adjunct therapy for acromegaly[J].J Clin Endocrinol Metab,1998,83(10):3419-3426.
  • 5Freda P U,Wardlaw S L,Post K D.Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly[J].J Neurosurg,1998,89(3):353-358.
  • 6毛志钢,王海军,何东升,徐伟光,冯雷.影响垂体生长激素腺瘤经蝶手术疗效的因素分析[J].中国微侵袭神经外科杂志,2006,11(4):151-153. 被引量:7
  • 7Vieira J O Jr,Cukiert A,Liberman B.Magnetic resonance imaging of cavernous sinus invasion by pituitary adenoma diagnostic criteria and surgical findings[J].Arq Neuropsiquiatr,2004,62 (28):437-443.
  • 8霍钢,郑履平,唐文渊.垂体腺瘤侵袭海绵窦的MRI判定标准[J].第四军医大学学报,2007,28(8):711-713. 被引量:9
  • 9Ludecke D K,Abe T.Transsphenoidal microsurgery for newly diagnosed acromegaly:a personal view after move than 1000 operations[J].Neuroendocrinology,2006,83 (3-4):230-239.
  • 10Mniniti G,Jaffrain-rea M L,Ostim M,et al.The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas[J].Clin Endocrinol Oxf,2005,62(2):210-216.

二级参考文献25

  • 1毛志钢,王海军,何东升,徐伟光,冯雷.影响垂体生长激素腺瘤经蝶手术疗效的因素分析[J].中国微侵袭神经外科杂志,2006,11(4):151-153. 被引量:7
  • 2Orme SM, Mcnally R J, Cartwright RA, et al . Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group [J]. J Clin Endoerinol Metab, 1998,83(8): 2730-2734.
  • 3Cottier JP, Destrieux C, Brtmereu L, et al . Cavernous sinus invasion by pituitary adenomas: MR Imaging [J]. Radiology, 2000, 215(2): 463-469.
  • 4Clemmons DR, Chihara K, Freda PU, et al . Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm [J]. J Clin Endocrinol Metab, 2003, 88:4759-4767.
  • 5Minniti G, Jaffrain-Rea ML, Esposito V, et al . Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature [J]. Endocr Relat Cancer, 2003, 10(4): 611-619.
  • 6Beauregard C, Truong U, Hardy J, et oi . Long-term out- come and mortality after transsphenoidal adenomectomy for acromegaly [J]. Clin Endocrinol (Oxf), 2003, 58(1): 86-91.
  • 7Santoro A, Minniti G, Ruggeri A, et al. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results [J]. Surg Neurol, 2007, 68(5): 513-518.
  • 8Bates AS, vant Hoff W, Jones JM, et al . Does treatment of acromegaly affect life expectancy [J]? Metabolism, 1995, 44(suppl 1):1-5.
  • 9Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1 000 operations IJ]. Neuroendocrinology, 2006, 83(3- 4): 230-239.
  • 10Oshino S, Saitoh Y, Kasayama S, et al . Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage [J]. Endocr J, 2006, 53(1): 125-132.

共引文献17

同被引文献24

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部